Similarly, another study showed that RESV increased the anticancer effects of PAX through upregulation of apoptosis and caspase 3 in non-small cell lung cancer [86] and HepG2 cancer cell lines [12, 87, 88]. The gene discussed is CASP3; the disease is non-small cell lung carcinoma.